Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center

Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy

(2011) F Cavallo et al.   LEUKEMIA

Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide

(2010) I N M Micallef et al.   BONE MARROW TRANSPLANTATION

Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen

(2010) A Nazha et al.   BONE MARROW TRANSPLANTATION

Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma

(2009) Uday Popat et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

(2009) S. Kumar et al.   BLOOD

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

(2009) S Giralt et al.   LEUKEMIA

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma

(2008) H Paripati et al.   LEUKEMIA